+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 57 Pages
  • April 2023
  • GlobalData
  • ID: 4125958
bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

bluebird bio Inc (bluebird bio) is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc Key Recent Developments

  • Jan 09, 2023: bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
  • Jan 03, 2023: Bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
  • Nov 07, 2022: bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
  • Sep 22, 2022: bluebird bio,appointed Katherine Breedis as a Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • bluebird bio Inc - Key Facts
  • bluebird bio Inc - Key Employees
  • bluebird bio Inc - Key Employee Biographies
  • bluebird bio Inc - Major Products and Services
  • bluebird bio Inc - History
  • bluebird bio Inc - Company Statement
  • bluebird bio Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • bluebird bio Inc - Business Description
  • R&D Overview
  • bluebird bio Inc - Corporate Strategy
  • bluebird bio Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • bluebird bio Inc - Strengths
  • bluebird bio Inc - Weaknesses
  • bluebird bio Inc - Opportunities
  • bluebird bio Inc - Threats
  • bluebird bio Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • bluebird bio Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jan 09, 2023: bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
  • Jan 03, 2023: Bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
  • Nov 07, 2022: bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
  • Sep 22, 2022: bluebird bio,appointed Katherine Breedis as a Chief Financial Officer
  • Sep 12, 2022: Bluebird bio : Board changes
  • Aug 04, 2022: bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
  • Jun 20, 2022: CombiGene comments on positive news for Bluebird
  • May 09, 2022: bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
  • Apr 05, 2022: bluebird bio initiates restructuring to reduce operating expenses and advance near-term opportunities to bring potentially curative gene therapies to patients in the US
  • Mar 07, 2022: bluebird bio announces personnel changes
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • bluebird bio Inc, Key Facts
  • bluebird bio Inc, Key Employees
  • bluebird bio Inc, Key Employee Biographies
  • bluebird bio Inc, Major Products and Services
  • bluebird bio Inc, History
  • bluebird bio Inc, Other Locations
  • bluebird bio Inc, Subsidiaries
  • bluebird bio Inc, Key Competitors
  • bluebird bio Inc, Ratios based on current share price
  • bluebird bio Inc, Annual Ratios
  • bluebird bio Inc, Interim Ratios
  • bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • bluebird bio Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • bluebird bio Inc, Performance Chart (2018 - 2022)
  • bluebird bio Inc, Ratio Charts
  • bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Intellia Therapeutics Inc
  • GlycoMimetics Inc
  • 4SC AG
  • Beam Therapeutics Inc
  • Bellicum Pharmaceuticals Inc
  • Sangamo Therapeutics Inc
  • Global Blood Therapeutics Inc
  • Intellia Therapeutics Inc
  • Sangamo Therapeutics Inc
  • Bellicum Pharmaceuticals Inc
  • 4SC AG
  • GlycoMimetics Inc
  • Beam Therapeutics Inc
  • Global Blood Therapeutics Inc
  • Acceleron Pharma Inc